Skip to main content

Bavencio Side Effects

Generic name: avelumab

Medically reviewed by Philip Thornton, DipPharm. Last updated on Dec 17, 2023.

Note: This document contains side effect information about avelumab. Some dosage forms listed on this page may not apply to the brand name Bavencio.

Applies to avelumab: intravenous solution.

Serious side effects of Bavencio

Along with its needed effects, avelumab (the active ingredient contained in Bavencio) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking avelumab:

More common

Less common

Rare

Other side effects of Bavencio

Some side effects of avelumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to avelumab: intravenous solution.

Cardiovascular

Very common (10% or more): Hypotension (25%), hypertension (13%)

Uncommon (0.1% to 1%): Myocarditis[Ref]

Dermatologic

Very common (10% or more): Urticaria (25%), rash (e.g., maculopapular, erythema, dermatitis bullous) (22%), pruritus (10%)

Uncommon (0.1% to 1%): Psoriasis, arthritis, exfoliative dermatitis, pemphigoid, Stevens Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), histiocytic necrotizing lymphadenitis, vasculitis, hypophysitis[Ref]

Endocrine

Common (1% to 10%): Immune-mediated thyroid disorders (hypothyroidism/hyperthyroidism)

Uncommon (0.1% to 1%): Adrenal insufficiency, hypopituitarism, hypophysitis[Ref]

Gastrointestinal

Very common (10% or more): Abdominal pain (25%), diarrhea (23%), nausea (22%), constipation (17%)

Common (1% to 10%): Immune-mediated colitis

Uncommon (0.1% to 1%): Pancreatitis[Ref]

Hematologic

Very common (10% or more): Lymphopenia (49%), anemia (35%), thrombocytopenia (27%)

Common (1% to 10%): Neutropenia

Rare (0.01% to 0.1%): Hemolytic anemia[Ref]

Hepatic

Very common (10% or more): Increased aspartate aminotransferase (AST) (34%), increased alanine aminotransferase (ALT) (20%)

Common (1% to 10%): Increased bilirubin

Uncommon (0.1% to 1%): Immune-mediated hepatitis[Ref]

Immunologic

Common (1% to 10%): Immunogenicity[Ref]

Local

Very common (10% or more): Anorexia (20%), weight loss (15%), increased lipase (14%)

Common (1% to 10%): Increased amylase[Ref]

Metabolic

Very common (10% or more): Anorexia (20%), weight loss (15%), increased lipase (14%)

Common (1% to 10%): Increased amylase[Ref]

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (32%), back pain (25%), arthralgia (16%)

Common (1% to 10%):

Uncommon (0.1% to 1%): Myositis, rhabdomyolysis, myasthenia gravis[Ref]

Nervous system

Very common (10% or more): Dizziness (14%), headache (10%)

Uncommon (0.1% to 1%): Guillain-Barre syndrome, demyelination, encephalitis[Ref]

Respiratory

Very common (10% or more): Couth (18%), dyspnea (11%)

Common (1% to 10%): Immune-mediated pneumonitis, wheezing[Ref]

Renal

Rare (less than 0.1%): Immune-mediated nephritis[Ref]

Other

Very common (10% or more): Fatigue (50%), pyrexia (25%), chills (25%), flushing (25%), peripheral edema (20%)[Ref]

Ocular

Uncommon (0.1% to 1%): Uveitis, iritis[Ref]

Frequently asked questions

References

1. Product Information. Bavencio (avelumab). EMD Serono Inc. 2017.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.